Key Takeaways
- • Century Health closed an oversubscribed $5 million seed round led by Origin Ventures, with participation from InnovateHealth Ventures, 25madison, Next Play Ventures, 2048 Ventures, and Alumni Ventures.
- • The company applies AI-powered data curation to transform fragmented clinical data into high-quality real-world evidence datasets for pharmaceutical and life sciences research collaborations.
- • Funding will support scaling partnerships with life sciences organizations, expanding the specialty provider data network, and developing AI-powered data infrastructure while maintaining patient privacy compliance.
- • Strategic angel investors include Zorba Lieberman, founder of Citeline, alongside clinicians specializing in nephrology, neurology, and ophthalmology, signaling domain expertise in the syndicate.
Summary
Century Health, a health technology company focused on real-world evidence generation, announced on May 19, 2026, the completion of an oversubscribed $5 million seed funding round. Origin Ventures led the investment, with participation from institutional and specialized healthcare-focused venture investors including InnovateHealth Ventures, 25madison, and Next Play Ventures. Existing backers 2048 Ventures and Alumni Ventures also participated in the round, demonstrating investor confidence in the company's early progress and market opportunity.
The company's core technology automates the extraction and enrichment of clinical data from fragmented healthcare information systems, leveraging artificial intelligence to create structured, analyzable datasets suitable for pharmaceutical research and life sciences applications. By automating manual data curation processes, Century Health addresses a persistent inefficiency in real-world evidence generation while maintaining stringent patient privacy standards. The platform operates through partnerships with academic institutions, healthcare providers, and life sciences organizations.
Capital deployment will prioritize three strategic areas: scaling research and use-case collaborations with pharmaceutical and life sciences partners, expanding the specialty provider data network to capture additional clinical populations, and developing enhanced AI-powered data infrastructure. The syndicate composition reflects targeted domain expertise, with Zorba Lieberman—founder of Citeline, a clinical trial information platform—joining as a strategic angel alongside practicing clinicians in nephrology, neurology, and ophthalmology. This clinical specialist involvement underscores Century Health's positioning within specialized therapeutic areas where fragmented data represents a significant research bottleneck.
The oversubscribed nature of the round signals strong market validation for real-world evidence platforms, particularly as pharmaceutical companies face pressure to de-risk clinical development pipelines and accelerate time-to-market for therapeutics. Century Health's ability to attract both generalist venture capital and specialized healthcare investors suggests broad recognition of the addressable market in clinical data infrastructure and AI-driven research enablement.
The company's core technology automates the extraction and enrichment of clinical data from fragmented healthcare information systems, leveraging artificial intelligence to create structured, analyzable datasets suitable for pharmaceutical research and life sciences applications. By automating manual data curation processes, Century Health addresses a persistent inefficiency in real-world evidence generation while maintaining stringent patient privacy standards. The platform operates through partnerships with academic institutions, healthcare providers, and life sciences organizations.
Capital deployment will prioritize three strategic areas: scaling research and use-case collaborations with pharmaceutical and life sciences partners, expanding the specialty provider data network to capture additional clinical populations, and developing enhanced AI-powered data infrastructure. The syndicate composition reflects targeted domain expertise, with Zorba Lieberman—founder of Citeline, a clinical trial information platform—joining as a strategic angel alongside practicing clinicians in nephrology, neurology, and ophthalmology. This clinical specialist involvement underscores Century Health's positioning within specialized therapeutic areas where fragmented data represents a significant research bottleneck.
The oversubscribed nature of the round signals strong market validation for real-world evidence platforms, particularly as pharmaceutical companies face pressure to de-risk clinical development pipelines and accelerate time-to-market for therapeutics. Century Health's ability to attract both generalist venture capital and specialized healthcare investors suggests broad recognition of the addressable market in clinical data infrastructure and AI-driven research enablement.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.